Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 8837609.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.
Medical subject headings
- Autoimmune Diseases
- Immunotherapy, Active
- Multiple Sclerosis
- Peptide Fragments
- Receptors, Antigen, T-Cell, alpha-beta
- Vaccines